Pretreatment circulating tumor cell levels are a reliable basis for selecting breast cancer patients for ablation

From the articleAblation Falls Short in Oligometastatic Breast Cancer TrialAlso in Randomized trial finds targeting individual metastases in oligometastatic breast cancer does not improve survival